4 views left Get unlimited views with a free account

Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center.

Alzheimer's Studies Fail to Meet Primary Goals, Claims Roche

Industry: Central Nervous System
Current: Product Indicators

Roche Holding AG said that the possible medication, gantenerumab, did not slow the clinical decline in patients with early Alzheimer's in both studies
In the experiments, gantenerumab eliminated less beta-amyloid than anticipated
The maximal annual sales potential of gantenerumab was $6 billion

Roche Holding AG’s Gantenerumab Fails

A much-anticipated experimental medicine for Alzheimer's disease failed in two significant tests, adding to the field's depressing history of research failures, according to Roche Holding AG, a pharmaceutical company based in Basel, Switzerland. According to Roche, the possible medication, gantenerumab, did not slow the clinical decline in patients with early Alzheimer's. Both studies failed to achieve their principal research goals.

Hopes for Roche's medication increased after a comparable medication achieved a significant milestone two months ago by becoming the first treatment to decrease the development of Alzheimer's in an objective trial. Roche had issued a warning, stating that the success of Biogen Inc. and Eisai Co.'s lecanemab did not necessarily imply that gantenerumab would likewise achieve its goals—especially given the field's history of failures.

The total number of clinical trials of drugs used to treat a progressive neurological disorder such as Alzheimer’s disease in 2022 among Asia Pacific, Europe, South and Central America, North America and Middle East & Africa– is found to be the highest in the North America, US, according to GlobalData.

Gantenerumab is an antibody that specifically targets the beta-amyloid protein, which builds up in the brain years before Alzheimer's symptoms manifest. In the experiments, it eliminated less beta-amyloid than anticipated. Investors were wary, and the majority did not think that the Roche tests would be successful. The maximal annual sales potential of gantenerumab was $6 billion. The Swiss pharmaceutical company simultaneously conducted two major studies to demonstrate the potential of gantenerumab for the benefit of patients.

Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center. Get a 360 degree view on a company powered by live data from the GlobalData Intelligence Center. Explore Company Solutions